News

August 6, 2018

Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma

News

The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing the investigational therapy. Orphan drug designation aims ... Read more

August 3, 2018

CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients

News

Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell transplant, has been recommended by ... Read more

August 1, 2018

Machine-learning Algorithm Predicts Responses to Myeloma Treatments

News

Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide) treatment, a study shows. Those findings ... Read more

July 30, 2018July 30, 2018

Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests

News

Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that would be missed by serum screenings, a ... Read more

July 27, 2018

Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients

News

Karyopharm Therapeutics is seeking accelerated approval for its investigational therapy selinexor in the United States as a treatment for heavily treated multiple myeloma patients. The company has begun the ... Read more

July 25, 2018

Ninlaro Could Replace First-line Velcade in Older Myeloma Patients, Study Suggests

News

Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead of standard Velcade (bortezomib), according to ... Read more

July 20, 2018

Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study

News

A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma in mice, a study reports. ... Read more

July 18, 2018

Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial

News

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase ... Read more

July 11, 2018

Early Relapse in Multiple Myeloma Linked to Greater Economic Burden in US

News

Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study shows. The findings highlight ... Read more

July 9, 2018July 9, 2018

Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows

News

Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to ... Read more